Amplifica
Amplifica, a clinical-stage biopharmaceutical company based in San Diego, has announced the results from its first-in-human trial of AMP-303, an intradermal injection treatment for androgenic alopecia (AGA). Amplifica has several AGA treatments in the pipeline, including AMP-203 (osteopontin) and AMP-601 (SCUBE3). What is AMP-303? We spoke about AMP-303 last year when they announced the initiation…
Read More
The Aesthetic Tech Forum 2024 is underway (January 25th and 26th) and features a session titled “Revitalizing Radiance: Advances in Hair Restoration“. Panelists include: Wajdie Ahmad, Executive Chairman & COO of Amplifica Holdings Group, Inc.; Amplifica is a biopharmaceutical company with several treatments in the pipeline targeted towards androgenic alopecia (AMP-303, AMP-203, and AMP-601). Drew…
Read More
On June 28, 2023, Amplifica Holdings Group announced the initiation of a clinical trial for one of its lead candidate molecules from the study of hairy moles. Amplifica’s AMP-303 has officially entered a clinical trial. According to a news release on the company’s website and PR Newswire, the first patient was dosed in a multicenter,…
Read More
Things are really heating up in the hair loss treatment industry on the first day of Summer 2023. Let’s take a look at all pertinent information and happenings in the AGA clinical trial world below. Cosmo Pharma Lists Phase 3 Trial On ClinicalTrials.gov A trial which was once highly anticipated, then questioned if it would…
Read More